PT  - JOURNAL ARTICLE
AU  - Estela de O. Lima
AU  - Tatiane M. Guerreiro
AU  - Carlos F. O. R. Melo
AU  - Diogo N. de Oliveira
AU  - Daisy Machado
AU  - Marcelo Lancelloti
AU  - Rodrigo R. Catharino
TI  - Zika virus infection induces synthesis of Digoxin in glioblastoma cells
AID  - 10.1101/174441
DP  - 2017 Jan 01
TA  - bioRxiv
PG  - 174441
4099  - http://biorxiv.org/content/early/2017/08/09/174441.short
4100  - http://biorxiv.org/content/early/2017/08/09/174441.full
AB  - Recently, microcephaly cases have increased in Americas and have been matter of concern due to Zika virus (ZIKV) recent outbreak. Previous studies have shown that ZIKV-infected progenitor neuronal cells present morphological abnormalities and increased rates of cell death, which may be indicators of microcephaly causes. As recent studies indicate Zika virus’ tropism for brain cells, how would a glioblastoma (GBM) lineage behave under ZIKV infection, considering GBM the most common and malignant brain tumor in adults, presenting extreme chemoresistance and high morbidity and mortality rates? The current trend of using genetically engineered oncolytic pathogens as a safe way to eliminate tumors is under development, with trials already in course. Therefore, the present study evaluated the possible oncolytic effects and metabolomic alterations of Zika virus infection at human malignant M059J glioblastoma cells. Microscopic evaluation was performed using optical microscopy, which showed cytopathic effects induced by ZIKV at GBM cells. For the metabolomics study, both control and infected cell cultures were submitted to MALDI-MSI analysis. Mass spectrometry data were submitted to PLS-DA statistical analysis, and distinct biomarkers were elected for each infected groups. This study brings light to unexpectedly induced metabolic changes, as endogenous Digoxin as important biomarker for ZIKV-GBM group, associated with cytopathic effects induced by viral infection. These results evidences that genetically engineered ZIKV might be a potential new strategy for neural cancer management through the induction of endogenous digoxin synthesis in glioblastoma cells.